United States: Xryem: Pharmaceutical Settlement Acceleration Clause Found Anticompetitive Due To Risk Of "Profit Crushing Competition" - Haug Partners

On August 13, 2021, in a decision that largely flew under antitrust and patent practitioners' radars, U.S. District Judge Lucy H. Koh mostly denied a motion to dismiss in the alleged "reverse payment" case...